Friday, May 11, 2018
CONTINENTAL BREAKFAST
7:00 - 8:00  
Introduction
8:00 - 8:15

Introduction to the Day’s Proceedings

Harley Eisman, MD, Co-Founder, Hereditary Breast and Ovarian Cancer Foundation, Montréal, QC, Canada

William Foulkes, MBBS, PhD, Director, Program in Cancer Genetics, McGill University, Montréal, QC, Canada

SESSION 9:
New and old genes for breast cancer
8:15 - 9:45

CHAIR: Alvaro Monteiro, PhD, Moffitt Cancer Center, Tampa, FL, USA

8:15 - 8:35

BRIDGES: A collaborative approach to identifying and validating breast cancer susceptibility genes

Peter Devilee, PhD, Leiden University Medical Centre, Leiden, The Netherlands

8:35 - 8:55

Validating new and old breast cancer susceptibility gene candidates – the Australian Approach

Ian Campbell, PhD, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia

8:55 - 9:05

Proffered paper 1
Breast cancer prevalence and clinical characteristics in carriers of ATM missense vs. loss-of-function variants

Katherine Skora, MS, MPH, CGC, GeneDx, Gaithersburg, MD, USA

9:05 - 9:15

Proffered paper 2
Multigene panel testing in BRCA1/2 mutation negative male breast cancer patients: Results from a multicenter study in Italy

Laura Ottini, MD, Sapienza University of Rome, Rome, Italy

9:15 - 9:25

Proffered paper 3
Utilization of pathogenic mutations beyond BRCA1/2 in breast cancer patients up to 36 months post-testing

Whitney Espinel, MMSc, Huntsman Cancer Institute, Salt Lake City, UT, USA

9:25 - 9:45

Question and discussion period (all speakers)

BREAK
9:45 - 10:15  
SESSION 10:
Modifying, classifying and assessing risk for HBOC
10:15 - 11:45

CHAIR: Marc Tischkowitz, MD, PhD, University of Cambridge, Cambridge, UK

10:15 - 10:35

Genetic modifiers of BRCA1/2: Are we ready for a polygenic risk score in the BRCA carrier clinic?

Antonis Antoniou, PhD, Cancer Risk Prediction, University of Cambridge, Cambridge, UK

10:35 - 10:55

Athena Breast Health Network: WISDOM for population-based personalized mammography screening

Laura van’t Veer, PhD, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA

10:55 - 11:05

Proffered paper 1
Polygenic risk from common genomic variants modifies the effect of many moderate risk breast cancer predisposition genes and can improve clinical interpretation.

Paul James, MBChB, DPhil, Peter MacCallum Cancer Centre, Melbourne, Australia

11:05 - 11:15

Proffered paper 2
Functional analysis of the RAD51C tumor suppressor

Fergus Couch, PhD, Mayo Clinic, Rochester, MN, USA

11:15 - 11:25

Proffered paper 3
A microsimulation model for optimizing BRCA mutation carrier cancer risk management: miBRovaCAre

Lara Petelin, BSc/LLB, PhD Student, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia

11:25 - 11:45

Question and discussion period (all speakers)

CLOSING SESSION
The Marla Miller Memorial Lecture
11:55 - 13:10

Introductory Remarks

William Foulkes, MBBS, PhD, Director, Program in Cancer Genetics, McGill University, Montréal, QC, Canada

Genomic analysis of inherited breast and ovarian cancer: from gene discovery to precision medicine and public health

Mary-Claire King, PhD, Medical Genetics and Genome Sciences, University of Washington School of Medicine, Seattle, WA, USA

Presentation by the Miller Family

Closingy Remarks

Harley Eisman, MD, Co-Founder, Hereditary Breast and Ovarian Cancer Foundation, Montréal, QC, Canada

Marla Miller-Gross
Marla Miller-Gross passed away less than two years after being diagnosed with "routine" breast cancer, months shy of her fortieth birthday. Marla's courage in opting for genetic testing has touched lives far far beyond those that she befriended while living.

Out of Marla's tragedy, HBOC was born and the drive to improve the outcome of women and families with hereditary breast and ovarian cancer.